News Sentiment

PTGX sentiment intelligence

Protagonist Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 62 Constructive news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 140.91 Week of 17 Jul 2026
Weighted tone 62/100

Constructive news tone

Market reaction News confirmed by price

Constructive news tone is being confirmed by positive weekly price action.

Primary event Market update

80/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+7.2% over one week, +24.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Protagonist Therapeutics (PTGX) Rises In Biotech Rally While Valuation Keeps The Debate Open

Market Reaction

News confirmed by price

72/100 confidence

Constructive news tone is being confirmed by positive weekly price action.

Primary event Market update 80/100 classification
One-week reaction 7.2% Price confirming higher
Trend fit Trend active 24.9% over four weeks
Fair value 170.3% Materially above fair value
Sentiment confirms active trend Positive but stretched

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 26
Neutral 31
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 17
simplywall.st 8
TradingView 6
Stock Titan 5
Quartr 4
AlphaStreet 3
GuruFocus 2
Simply Wall Street 2

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 15
Analyst action 8
Regulatory and legal 2
Balance sheet 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 58
AlphaStreet Direct company coverage

Protagonist Therapeutics Jumps 5.7% Amid Sector-Wide Rally

Protagonist Therapeutics saw its shares surge 5.7% on Friday, closing at $139.60, as the biotech company benefited from a broad sector-wide rally. This synchronized movement among biotechnology stocks suggests that macro factors and a shift in investor risk appetite, rather than

Tone
Positive 72/100
Event
Market update
Published
17 Jul 2026 17:10
Source
AlphaStreet
Market source Direct company coverage

Protagonist Therapeutics Reports Granting of Inducement Awards

Protagonist Therapeutics granted inducement awards to three new employees, consisting of options to purchase 12,600 shares and RSUs for 3,330 shares of common stock. These awards were made under its Amended and Restated Inducement Plan, with vesting periods of four years for both

Tone
Positive 64/100
Event
Market update
Published
17 Jul 2026 11:09
Source
Market source
Investing.com Canada Direct company coverage

Citizens raises Protagonist Therapeutics price target on Icotyde uptake By Investing.com

Citizens increased its price target for Protagonist Therapeutics (NASDAQ: PTGX) to $165 from $137, while maintaining a Market Outperform rating, due to better-than-expected prescription volume for its drug Icotyde. The firm now estimates approximately $8 million in second-quarter

Tone
Positive 72/100
Event
Analyst action
Published
17 Jul 2026 09:58
Source
Investing.com Canada
Stock Titan Direct company coverage

Three New Hires Receive Protagonist Options and RSUs Under Inducement Plan

Protagonist Therapeutics (Nasdaq: PTGX) granted equity inducement awards to three new employees on July 15, 2026. These awards include options for 12,600 shares and RSUs for 3,330 shares, with an option exercise price of $135.46. The awards were approved by the compensation commi

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 20:11
Source
Stock Titan
AlphaStreet Direct company coverage

Protagonist Therapeutics Jumps 5.3% After Barclays Maintains Overweight

Protagonist Therapeutics saw its shares jump 5.3% to $138.27 after Barclays maintained an Overweight rating and significantly raised its price target by 26.9% to $151. This upgrade reflects increasing confidence in the biotechnology company's prospects, driving keen investor inte

Tone
Positive 93/100
Event
Analyst action
Published
16 Jul 2026 10:39
Source
AlphaStreet
GuruFocus Direct company coverage

PTGX Maintained by Barclays -- Price Target Raised to $151

Barclays has maintained an "Overweight" rating for Protagonist Therapeutics (PTGX) and increased its price target from $119.00 to $151.00, signaling confidence in the company's biotech potential. While analysts are optimistic, GuruFocus indicates that PTGX is significantly overva

Tone
Neutral 50/100
Event
Analyst action
Published
14 Jul 2026 12:39
Source
GuruFocus
Quartr Direct company coverage

Protagonist Therapeutics (PTGX) AGM 2026 Summary

This article summarizes Protagonist Therapeutics' (PTGX) 2026 Annual General Meeting (AGM). Key topics included the election of directors, an advisory vote on executive compensation, ratification of the auditor (Ernst & Young), and approval of the 2026 equity incentive plan. The

Tone
Neutral 50/100
Event
Regulatory and legal
Published
11 Jul 2026 09:12
Source
Quartr
Quartr Direct company coverage

Protagonist Therapeutics (PTGX) Investor Update Summary

Protagonist Therapeutics (PTGX) announced positive phase III VERIFY study results for Rusfertide in polycythemia vera, meeting primary and secondary endpoints with significant efficacy and improved patient-reported outcomes. The drug was well-tolerated with no new safety signals.

Tone
Positive 93/100
Event
Earnings
Published
11 Jul 2026 09:10
Source
Quartr
Quartr Direct company coverage

Protagonist Therapeutics (PTGX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary

This article summarizes Protagonist Therapeutics' presentation at the Goldman Sachs 47th Annual Global Healthcare Conference in 2026. The company is transitioning to a commercial stage, anticipating approval for Rusfertide, and boasts a strong financial position due to product la

Tone
Positive 93/100
Event
Regulatory and legal
Published
11 Jul 2026 08:39
Source
Quartr
Simply Wall Street Direct company coverage

Will Icotyde’s Launch and Rusfertide’s Priority Review Change Protagonist Therapeutics’ (PTGX) Narrative

Protagonist Therapeutics (PTGX) has experienced a significant shift in its investment narrative due to the U.S. launch of its psoriasis drug Icotyde and the FDA priority review for its polycythemia vera candidate rusfertide, with an action date in August 2026. This marks a transi

Tone
Positive 65/100
Event
Market update
Published
10 Jul 2026 21:10
Source
Simply Wall Street
Simply Wall Street Direct company coverage

Protagonist Therapeutics (PTGX) Could Be 66% Below Fair Value As Pipeline Progress Lifts Interest

Protagonist Therapeutics (PTGX) saw its stock climb 7.1% due to investor focus on key pipeline milestones and recent FDA activity related to rusfertide and Icotyde. Despite a P/B ratio of 13.7x, which is high compared to the broader US biotech sector, a discounted cash flow (DCF)

Tone
Positive 78/100
Event
Balance sheet
Published
09 Jul 2026 07:41
Source
Simply Wall Street
Quartr Direct company coverage

Protagonist Therapeutics (PTGX) Q1 2026 earnings summary

Protagonist Therapeutics reported a strong Q1 2026 driven by FDA approval for ICOTYDE, triggering a $50M milestone payment, and a strategic opt-out of U.S. profit-sharing for rusfertide with Takeda, resulting in a $200M payment. The company achieved significant revenue growth and

Tone
Positive 91/100
Event
Earnings
Published
08 Jul 2026 20:10
Source
Quartr
Market source Direct company coverage

Protagonist Therapeutics (PTGX) Surges 7.1%: Is This an Indication of Further Gains?

Protagonist Therapeutics (PTGX) stock saw a significant 7.1% rally, closing at $140.85, driven by investor confidence in its late-stage drug candidate rusfertide and expanding commercial opportunities for Icotyde. The FDA has accepted a new drug application for rusfertide with pr

Tone
Positive 70/100
Event
Market update
Published
08 Jul 2026 10:30
Source
Market source
Investing.com Nigeria Direct company coverage

Truist raises Protagonist Therapeutics stock price target on Icotyde outlook By Investing.com

Truist Securities has increased its price target for Protagonist Therapeutics Inc. (NASDAQ: PTGX) to $145 from $121, maintaining a Buy rating, based on the strong commercial potential of its drug Icotyde. Johnson & Johnson, Protagonist's commercial partner, has highlighted Icotyd

Tone
Neutral 50/100
Event
Analyst action
Published
07 Jul 2026 19:42
Source
Investing.com Nigeria
StocksToTrade Direct company coverage

PTGX Stock Grinds Higher As Pipeline Catalysts Build

Protagonist Therapeutics (PTGX) stock rose over 7% following positive drug development news. The company launched ICOTYDE in the U.S. for psoriasis and has rusfertide under FDA priority review for polycythemia vera, alongside ongoing Phase 3 trials for ICOTYDE in other inflammato

Tone
Positive 75/100
Event
Market update
Published
07 Jul 2026 19:40
Source
StocksToTrade
AD HOC NEWS Direct company coverage

Protagonist Therapeutics updates its clinical pipeline. PTGX focuses on peptide-based therapies

Protagonist Therapeutics (PTGX) is a clinical-stage biopharmaceutical company focused on developing peptide-based therapies for inflammatory and hematologic diseases. The Nasdaq-listed company aims to advance its multi-program pipeline through clinical trials, differentiating its

Tone
Positive 66/100
Event
Market update
Published
07 Jul 2026 17:11
Source
AD HOC NEWS
AlphaStreet Direct company coverage

Protagonist Therapeutics Jumps 5.2% Amid Sector-Wide Rally

Protagonist Therapeutics (PTGX) saw its shares rise by 5.2% on Tuesday, closing at $138.29, due to a broad rally across the biotechnology sector. This increase was part of a coordinated move, with several peer companies also experiencing similar gains, suggesting a sector-wide mo

Tone
Positive 67/100
Event
Market update
Published
07 Jul 2026 16:40
Source
AlphaStreet
TradingView Direct company coverage

PTGX Stock Surges 64% in Six Months: What Is Driving the Rally?

Protagonist Therapeutics (PTGX) stock has surged 64% in the last six months, driven by progress in its rare hematology candidate rusfertide, the commercial expansion of its immunology therapy Icotyde, and advancements in its pipeline assets. The FDA's priority review of rusfertid

Tone
Positive 95/100
Event
Market update
Published
07 Jul 2026 15:11
Source
TradingView
GuruFocus Direct company coverage

PTGX Maintained by Truist Securities -- Price Target Raised to $145.00

Truist Securities has reiterated a 'Buy' rating for Protagonist Therapeutics (PTGX), increasing the price target from $121.00 to $145.00, indicating optimism about its pipeline. Despite this, GuruFocus assesses PTGX as 114.6% overvalued with a GF Value™ of $61.27, and its GF Scor

Tone
Neutral 50/100
Event
Analyst action
Published
07 Jul 2026 13:11
Source
GuruFocus
TradingView Direct company coverage

Price to sales forward of Protagonist Therapeutics, Inc. – NASDAQ:PTGX

This article provides financial data for Protagonist Therapeutics, Inc. (NASDAQ: PTGX), specifically focusing on its forward price-to-sales ratio. It lists the company's ticker, stock market, and highlights its current financial and market status.

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 11:11
Source
TradingView
Moomoo Direct company coverage

Truist Raises Price Target on Protagonist Therapeutics to $145 From $121, Keeps Buy Rating

Truist has increased its price target for Protagonist Therapeutics (PTGX) to $145 from $121, while maintaining a Buy rating on the stock. This news follows the company's Q4 financial results where Unity Software (U.US) reported significant revenue growth, though the article seems

Tone
Positive 77/100
Event
Analyst action
Published
07 Jul 2026 10:40
Source
Moomoo
Investing.com Direct company coverage

Truist raises Protagonist Therapeutics stock price target on Icotyde outlook

Truist Securities has increased its price target for Protagonist Therapeutics (NASDAQ: PTGX) to $145 from $121, maintaining a Buy rating, based on the strong commercial outlook for its drug Icotyde in psoriasis treatment. Johnson & Johnson, Protagonist's commercial partner, proje

Tone
Positive 74/100
Event
Analyst action
Published
07 Jul 2026 06:52
Source
Investing.com
TradingView Direct company coverage

Enterprise value to EBIT forward of Protagonist Therapeutics, Inc. – NASDAQ:PTGX

This article provides financial information for Protagonist Therapeutics, Inc. (NASDAQ: PTGX), specifically focusing on its enterprise value to EBIT forward. It appears to be a stub or a data page from TradingView, displaying the current market status and various navigation optio

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 19:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Protagonist Therapeutics, Inc. – NASDAQ:PTGX

The article provides the enterprise value to revenue forward for Protagonist Therapeutics, Inc. (NASDAQ: PTGX). It presents basic financial and market information for the company as listed on TradingView, covering its Nasdaq Stock Market data.

Tone
Neutral 50/100
Event
Earnings
Published
06 Jul 2026 15:43
Source
TradingView